An open label positron emission tomography [PET] study in healthy male subjects to investigate brain dopamine D3 occupancy kinetics, pharmacokinetics and safety of single oral doses of GSK598809, using [11C]-(+)-PHNO as PET ligand
Latest Information Update: 28 Jun 2023
At a glance
- Drugs GSK 598809 (Primary)
- Indications Eating disorders; Smoking withdrawal; Substance-related disorders
- Focus Pharmacokinetics
- Sponsors GSK
- 11 May 2007 New trial record.